cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Halozyme Therapeutics Inc
6 own
10 watching
Current Price
$0
$-0.76
(-1.44%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
7,148.61M
52-Week High
52-Week High
59.46
52-Week Low
52-Week Low
31.9955
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
14.5971
iconMarket Capitalization7,148.61M
icon52-Week High59.46
icon52-Week Low31.9955
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio14.5971
What does the Halozyme Therapeutics Inc do?
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More
How much money does Halozyme Therapeutics Inc make?
News & Events about Halozyme Therapeutics Inc.
Zolmax
20days ago
Halozyme Therapeutics (NASDAQ:HALO Get Rating) had its price target decreased by SVB Leerink from $62.00 to $61.00 in a research report released on Wednesday, Benzinga reports. SVB Leerink currently has an outperform rating on the biopharmaceutical companys stock. SVB Leerink also issued estimates ...
PR Newswire
1month ago
Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO, Jan. 3, 2023 SAN DIEGO, Jan. 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ('Halozyme') today...
Zolmax
2 months ago
Halozyme Therapeutics (NASDAQ:HALO Get Rating) had its price target raised by JPMorgan Chase & Co. from $53.00 to $54.00 in a research report sent to investors on Tuesday , Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical companys stock. Several ...
Ticker Report
2 months ago
Halozyme Therapeutics (NASDAQ:HALO Get Rating) had its price target lifted by JPMorgan Chase Co. from $53.00 to $54.00 in a report issued on Tuesday, Benzinga reports. JPMorgan Chase Co. currently has an overweight rating on the biopharmaceutical companys stock. Other ...
Frequently Asked Questions
Frequently Asked Questions
What is Halozyme Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Halozyme Therapeutics Inc shares?
plus_minus_icon
How can I buy Halozyme Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Halozyme Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Halozyme Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Halozyme Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Halozyme Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Halozyme Therapeutics Inc?
plus_minus_icon
What percentage is Halozyme Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Halozyme Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.76
(-1.44%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00